Chronic Kidney Disease Market Intelligence Report Covers Trends, Segments And Regional Growth

The chronic kidney disease (CKD) market is on a trajectory of significant expansion, driven by advancements in treatment options and growing awareness of kidney health. As innovations continue to emerge and patient-focused care gains prominence, this sector is expected to experience strong growth in the coming years. Below is a detailed overview of the market's size, leading players, trends, and key segments shaping its future.

Projected Growth and Size of the Chronic Kidney Disease Market
The market for chronic kidney disease is forecasted to reach $101.87 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.4%. This upward trend is propelled by several factors, including the ongoing development of innovative renal therapies, a rising demand for dialysis options tailored to patients' lifestyles, and the expansion of digital tools for monitoring kidney health. Additionally, increased efforts to prepare patients for transplants and growing investments in preventive nephrology are key contributors. Important trends anticipated during the forecast period include a stronger focus on early CKD detection, wider adoption of renoprotective drug treatments, greater use of home dialysis technologies, growth in multidisciplinary care models, and intensified initiatives to slow disease progression.

The chronic kidney disease market size has grown strongly in recent years. It will grow from $74.87 billion in 2025 to $79.43 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rising prevalence of diabetes and hypertension, increased availability of dialysis infrastructure, improved kidney function diagnostics, growing awareness of chronic renal disorders, expansion of nephrology care services.

Download a free sample of the chronic kidney disease market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11969&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Driving the Chronic Kidney Disease Market
Several prominent players dominate the CKD market landscape, such as Pfizer Inc, Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, and ProKidney Corp.

Significant Industry Acquisition Enhancing AstraZeneca's Cardiorenal Portfolio
In January 2023, AstraZeneca Pharmaceuticals LP, a biopharmaceutical company based in the US, completed its acquisition of CinCor Pharma Inc. for $1.8 billion. This deal brought CinCor's promising drug candidate, baxdrostat (CIN-107), into AstraZeneca's portfolio. Baxdrostat is an aldosterone synthase inhibitor (ASI) designed to manage blood pressure in patients with treatment-resistant hypertension. CinCor Pharma Inc. is a clinical-stage biopharmaceutical firm focused on developing therapies for resistant hypertension and chronic kidney disease, making this acquisition a strategic addition to AstraZeneca's cardiorenal pipeline.

View the full chronic kidney disease market report:
https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Collaborative Efforts Advancing Automated Wearable Dialysis Technology
Companies in the CKD field are increasingly forming strategic partnerships to improve technologies like the Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. Such collaborations allow organizations to combine resources and expertise for mutual benefit. For example, in June 2023, Singapore-based medical technology firm AWAK Technologies Pte Ltd. joined forces with Singapore General Hospital Pte Ltd. (SGH), an academic health science center. Their partnership focuses on developing and testing the AWAK PD system, a wearable and highly portable peritoneal dialysis device that enables patients with end-stage kidney disease to receive dialysis at home or while on the move, revolutionizing disease management and treatment convenience.

Breakdown of Key Segments Within the Chronic Kidney Disease Market
This market is segmented comprehensively across multiple categories to capture its wide scope.
1) Diagnosis Methods: Blood Test, Urine Test, Imaging Test, Kidney Biopsy
2) Treatment Options: Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Other Treatments
3) Routes of Administration: Oral, Intravenous, Subcutaneous
4) End-User Categories: Hospitals and Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers, Other End-Users

Detailed subcategories include:
- Blood Tests such as Serum Creatinine Test, Glomerular Filtration Rate (GFR) Test, Blood Urea Nitrogen (BUN) Test, and Electrolyte Tests
- Urine Tests including Urinalysis, 24-hour Urine Collection, Urine Protein Test, and Urine Albumin-to-Creatinine Ratio (ACR)
- Imaging Tests covering Ultrasound, CT Scan, MRI, and X-Ray
- Kidney Biopsies classified into Percutaneous, Open, and Laparoscopic types

Together, these segments provide a thorough understanding of the CKD market's structure and areas of focus, aiding stakeholders in navigating this evolving healthcare landscape.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.